Breast cancer is a highly heterogeneous tumor, and the traditional pathomorphological staging has gradually shown its imperfection in the current clinical practice. With the completion of the Human Genome Project and the application of molecular biology techniques, the concept of molecular staging based on tumor morphology combined with gene expression characteristics has been recognized by scholars. The genotype and clinicopathological characteristics of each molecular subtype of breast cancer Luminal A: the most common molecular subtype of breast cancer, with incidence rate of 44.5%-69.0%, ER and/or PR+, Her-2 C, best prognosis. Endocrine therapy has the best outcome. Endocrine therapy (± chemotherapy) is often used. Pre-menopausal often choose triamcinolone acetonide, pharmacological depot drug Norelide, post-menopausal often choose aromatase inhibitors such as anastrozole, letrozole, etc. Luminal B: 7.8% of luminal B breast cancers are ER and/or PR+, Her-2+, endocrine therapy is still effective and has a better prognosis. luminal B breast cancers are less responsive to tamoxifen than luminal A due to positive HER2 expression, but endocrine therapy with other mechanisms of action is still effective. Treatment is often chemotherapy + endocrine therapy + targeted therapy. Her-2 overexpression type: 14.7% incidence rate, ER and/or PR C, Her-2+, endocrine ineffective, chemotherapy is more effective and is an indication for HER2-targeted therapy, Her2(+) breast cancer is significantly more effective than luminal type, with clinical remission rate up to 70 The clinical remission rate of the former was up to 70%, compared with 47% for the latter. Although this type is more sensitive to chemotherapy, the clinical prognosis is poor. Chemotherapy + targeted therapy is often used, and 1 year of Herceptin treatment reduces the relative risk of recurrence by 52% and increases disease-free survival by 12% at 3 years. Basal-like type: incidence of 17.1%, ER and/or PRC, Her-2C, endocrine ineffective, chemotherapy effective, worst prognosis. Its metastases occur mostly in the viscera and central nervous system. Treatment options are chemotherapy. Among breast cancer patients receiving preoperative neoadjuvant chemotherapy (AC), the overall response rate and pathologic remission rate are high, with 85% of patients showing clinical remission and 27% of them achieving complete pathologic remission, which is significantly higher than that of luminal breast cancer. Although sensitive to preoperative neoadjuvant chemotherapy and with a high rate of pathological remission, the prognosis is still the worst among the molecular subtypes of breast cancer. Breast cancers with identical pathological patterns are highly heterogeneous at the molecular level due to molecular genetic alterations, resulting in a wide range of prognosis and response to treatment. Breast cancer genotyping, however, proposed based on gene expression profiling and gene microarrays, can more accurately respond to the biological behavior of tumors, determine prognosis, and facilitate the selection and study of more targeted and personalized treatments. An individualized and systematic treatment plan should be developed according to each patient’s molecular typing and other relevant factors.